Navidea Biopharmaceuticals (NAVB) Competitors $0.0005 0.00 (-50.00%) (As of 09:32 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsTrends NAVB vs. SEEL, NEXI, BDRX, PRFX, VAXX, SMFL, TCON, CALA, STAB, and SCPSShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Seelos Therapeutics (SEEL), NexImmune (NEXI), Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), Vaxxinity (VAXX), Smart for Life (SMFL), TRACON Pharmaceuticals (TCON), Calithera Biosciences (CALA), Statera Biopharma (STAB), and Scopus BioPharma (SCPS). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Seelos Therapeutics NexImmune Biodexa Pharmaceuticals PainReform Vaxxinity Smart for Life TRACON Pharmaceuticals Calithera Biosciences Statera Biopharma Scopus BioPharma Navidea Biopharmaceuticals (NYSE:NAVB) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk. Do insiders & institutionals have more ownership in NAVB or SEEL? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 23.4% of Seelos Therapeutics shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 1.1% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate NAVB or SEEL? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ASeelos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has higher valuation and earnings, NAVB or SEEL? Navidea Biopharmaceuticals has higher earnings, but lower revenue than Seelos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$70K0.71-$15.18M-$0.06-0.01Seelos Therapeutics$2.20M0.19-$37.88MN/AN/A Does the media refer more to NAVB or SEEL? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than Seelos Therapeutics. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for Seelos Therapeutics. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Seelos Therapeutics'average media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Seelos Therapeutics Neutral Does the MarketBeat Community prefer NAVB or SEEL? Seelos Therapeutics received 71 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 66.36% of users gave Seelos Therapeutics an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformNavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes62100.00% Seelos TherapeuticsOutperform Votes7166.36% Underperform Votes3633.64% Is NAVB or SEEL more profitable? Seelos Therapeutics has a net margin of 203.13% compared to Navidea Biopharmaceuticals' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Seelos Therapeutics 203.13%N/A -431.47% Which has more volatility and risk, NAVB or SEEL? Navidea Biopharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. SummarySeelos Therapeutics beats Navidea Biopharmaceuticals on 6 of the 11 factors compared between the two stocks. Ad Weiss RatingsThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”Click here to find out more about what could be Trump and JD Vance’s favorite coin. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$50,000.00$2.57B$5.02B$19.32BDividend YieldN/A0.70%7.49%3.57%P/E Ratio-0.015.94127.0841.85Price / Sales0.7130.241,683.1817.80Price / CashN/A15.5136.9020.54Price / Book0.003.064.585.30Net Income-$15.18M$29.98M$113.81M$982.74M7 Day PerformanceN/A-5.01%111.02%2.06%1 Month PerformanceN/A0.55%125.11%1.77%1 Year PerformanceN/A-5.01%155.23%23.76% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00-50.0%N/AN/A$50,000.00$70,000.00-0.0110Gap DownSEELSeelos TherapeuticsN/A$1.03+1.0%N/A-99.9%$380,000.00$2.20M0.0020Gap UpNEXINexImmuneN/A$0.22-40.4%N/A-92.5%$308,000.00N/A-0.0170BDRXBiodexa Pharmaceuticals1.8014 of 5 stars$5.91-3.9%$200.00+3,284.1%N/A$304,000.00$83,000.000.0021PRFXPainReform1.7704 of 5 stars$0.45-10.0%$2.00+344.5%-80.9%$290,000.00N/A-0.014Gap DownVAXXVaxxinityN/A$0.00flatN/A-99.8%$254,000.00$70,000.000.0090Gap UpSMFLSmart for LifeN/A$0.03+50.0%N/A-99.8%$213,000.00$8.23M0.00110TCONTRACON Pharmaceuticals1.408 of 5 stars$0.05flat$60.00+112,364.9%-98.2%$182,000.00$12.05M0.0120Gap UpHigh Trading VolumeCALACalithera BiosciencesN/A$0.01flatN/A-76.7%$30,000.00$9.75M0.0060News CoverageGap UpSTABStatera BiopharmaN/A$0.00flatN/A-97.0%$20,000.00$1.49M0.0020SCPSScopus BioPharmaN/A$0.00flatN/AN/A$17,000.00N/A0.009 Related Companies and Tools Related Companies Seelos Therapeutics Competitors NexImmune Competitors Biodexa Pharmaceuticals Competitors PainReform Competitors Vaxxinity Competitors Smart for Life Competitors TRACON Pharmaceuticals Competitors Calithera Biosciences Competitors Statera Biopharma Competitors Scopus BioPharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NAVB) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
